OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics" Spotlight Panel at BioFuture 2025 taking place at Cure in New York City on October 13, 2025 at 11:00am EDT. A virtual partnering option is offered October 21-23, 2025, including access to the event's recorded content. Company management will provide an overview of OS Therapies, with a particular emphasis on the clinical development and commercial plans for OST-HER2.

The Company is positioned to commence submission of a Biologics Licensing Application ("BLA") request to the United States Food & Drug Administration ("FDA") in the fourth quarter of 2025. If approved prior to September 30, 2026, the Company will become eligible to receive a priority review voucher ("PRV") that it intends to sell. PRV proceeds will continue further clinical development of OST-HER2 into other osteosarcoma-related indications, and into breast cancer and other HER2 positive cancers. Additionally, the Company would use proceeds to advance the other clinical candidates in its pipeline, including OST-504 in prostate cancer and OST-503 in the treatment of non-small cell lung cancer ("NSCLC") and other solid tumors.

"BioFuture 2025 is one of the premier meetings in the biotechnology sector, and we are honored to be invited to participate in the Cancer spotlight panel," said Paul Romness, MPH, Chair & CEO of OS Therapies. "The story of how OS Therapies has leveraged over $300 million in invested capital into our listeria monocytogenes platform technology (the "Listeria Platform") to potentially bring the first new treatment to market for osteosarcoma in over 40 years is compelling. What makes it even more compelling is the fact that multiple drug candidates from this platform have the potential to be additive to the standard of care (SOC) in a wide range of cancers where SOC ultimately leads to treatment resistance and fails. Given the strong safety profile of the investigational/pre-licensure Listeria Platform - and imminent transition to commercialization for the lead therapeutic - we see its potential to be applied across the spectrum of disease, helping to reduce cancer evolution and significantly extend the efficacy runway of SOC in large therapeutic indications that would ultimately lead to improved overall survival and quality of life for patients."